Boston Scientific Management
Management criteria checks 3/4
Boston Scientific's CEO is Mike Mahoney, appointed in Oct 2011, has a tenure of 13.08 years. total yearly compensation is $18.72M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $156.52M. The average tenure of the management team and the board of directors is 8.6 years and 8.3 years respectively.
Key information
Mike Mahoney
Chief executive officer
US$18.7m
Total compensation
| CEO salary percentage | 7.5% |
| CEO tenure | 13.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 8.6yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Compensation vs Market: Mike's total compensation ($USD18.72M) is above average for companies of similar size in the US market ($USD12.74M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
CEO
Mike Mahoney (59 yo)
13.1yrs
Tenure
US$18,723,735
Compensation
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$18.72m | 0.12% $ 156.5m | |
| Executive VP & CFO | 10.8yrs | US$5.83m | 0.015% $ 20.2m | |
| Executive VP & Group President of Cardiology | 14.8yrs | US$5.59m | 0.011% $ 15.0m | |
| Executive VP & President of Peripheral Interventions | 11.8yrs | US$3.78m | 0.0019% $ 2.5m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.3yrs | US$4.27m | 0.0016% $ 2.2m | |
| Executive Vice President of Global Operations | 2.5yrs | no data | 0.0025% $ 3.4m | |
| Senior VP | less than a year | no data | 0.00026% $ 346.6k | |
| Senior VP and Chief Information & Digital Officer | 8.9yrs | no data | no data | |
| Senior VP of Investor Relations | less than a year | no data | 0.0026% $ 3.4m | |
| Senior VP | 3.4yrs | no data | 0.0023% $ 3.1m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.5yrs | no data | no data | |
| Executive Vice President of Human Resources | 11.9yrs | no data | 0.0022% $ 2.9m |
8.6yrs
Average Tenure
56yo
Average Age
Experienced Management: BSX's management team is seasoned and experienced (8.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12yrs | US$18.72m | 0.12% $ 156.5m | |
| Lead Independent Director | 10.7yrs | US$360.00k | 0.0030% $ 4.0m | |
| Independent Director | 8.6yrs | US$335.00k | 0.0033% $ 4.4m | |
| Independent Director | 8.3yrs | US$320.00k | 0.00020% $ 266.6k | |
| Independent Director | 3.4yrs | US$338.75k | 0.0027% $ 3.6m | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | 0.00024% $ 319.9k | |
| Independent Director | 9.6yrs | US$326.25k | 0.0043% $ 5.7m | |
| Independent Director | 15.6yrs | US$340.00k | 0.0036% $ 4.8m | |
| Independent Director | 1.4yrs | US$233.23k | 0.00042% $ 559.9k | |
| Independent Director | 1.4yrs | US$233.23k | 0.00027% $ 359.9k |
8.3yrs
Average Tenure
60.5yo
Average Age
Experienced Board: BSX's board of directors are considered experienced (8.3 years average tenure).